Unione Europea - italiano - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin benzoato, metformina cloridrato - diabete mellito, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico per migliorare il controllo glicemico in pazienti con insulina a una dose stabile e metformina da sola non forniscono un adeguato controllo glicemico.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - alogliptinum, metformini hydrochloridum - compresse rivestite con film - alogliptinum 12.5 mg per alogliptini benzoas, metformini hydrochloridum 850 mg, excipiens pro compresso haze. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - alogliptinum, metformini hydrochloridum - compresse rivestite con film - alogliptinum 12.5 mg per alogliptini benzoas, metformini hydrochloridum 1000 mg, excipiens pro compresso haze. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - alogliptinum, metformini hydrochloridum - compresse rivestite con film - alogliptinum 12.5 mg per alogliptini benzoas, metformini hydrochloridum 500 mg, excipiens pro compresso haze. - farmaco antidiabetico orale - synthetika